Roche Holding AG (RHHVF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 03:15PM EDT
| Previous Close | 236.00 |
| Open | 239.17 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 234.20 - 240.24 |
| 52 Week Range | 234.20 - 323.78 |
| Volume | |
| Avg. Volume | 10,539 |
| Market Cap | 193.009B |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | 14.97 |
| EPS (TTM) | 15.72 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 10.86 (4.60%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
- Thomson Reuters StreetEvents
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Q1 2024 Sarepta Therapeutics Inc Earnings Call
CNW GroupCQDM, Roche, the Jewish General Hospital Foundation and McGill University fund research project of more than $9.4M on diabetic kidney disease
CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of the leading causes of kidney failure. This project, with a total value of over $9.4M, is made possible thanks to a $1.5M grant from the Quebec government (MEIE) awarded by CQDM, as well as a $2.4M financial contribution from Hoffmann-La Roche Limited (Roche) and another $2.8M from the Jewish General Hospital Foundation, and nearly $2
© 2024 Yahoo. All rights reserved.